drugset / Trial / NCT00248625

N-acetylcysteine in Non-Acetaminophen Pediatric Acute Liver Failure

NCT00248625

RandomizedParallel-groupTriple-blindTreatment

Summary

We have completed patient enrollment in the the double blind, randomized, placebo-controlled trial of intravenous (IV) N-acetylcysteine (NAC) vs. placebo for the treatment of non-acetaminophen ALF. The purpose of this study is to examine the safety and efficacy of intravenous NAC in children with ALF for whom no antidote or other specific treatment is available. Inclusion in the NAC Study required enrollment in the Pediatric Acute Liver Failure (PALF) Study Registry.

Timeline

Start
2000-01
Primary completion
2009-09
Completion
2010-10

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator N-acetylcysteine Small molecule 150 mg/kg Intravenous